WO
William O'Riordan
Credentials: ·
Research
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
New England Journal of Medicine · 2018 · 2,387 citations
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine · 2021 · 427 citations
Single-dose oritavancin in the treatment of acute bacterial skin infections
New England Journal of Medicine · 2014 · 252 citations
- GC
15 papers
5 papers
- PM
4 papers
- SO
4 papers
- SG
4 papers
- TF
4 papers
4 papers
- BH
3 papers
